IceCure shares surge 10.28% intraday after FDA authorizes ProSense for breast cancer treatment, driving Q4 sales.

IceCure Medical surged 10.28% intraday after disclosing record Q4 North American sales driven by rapid adoption of its FDA-authorized ProSense cryoablation system for low-risk breast cancer treatment in women aged 70+. The company highlighted strong orders from top U.S. hospital networks and increased market visibility, with preliminary revenue results expected in January 2026. The October 2025 FDA clearance and growing demand from hospitals and radiologists underpinned the optimism, aligning with the stock’s sharp intraday rally.